MAY 03, 2017 1:47 PM PDT

Lung Cancer's Return Can be Predicted a Year in Advance

WRITTEN BY: Xuan Pham

Results from a new study could help doctors detect the recurrence of lung cancer up to a year before traditional tests. Such technology would allow patients to stay one step ahead of the cancer in terms of treatment and survival outcomes.

The new test relies on circulating tumor DNA (ctDNA). Also known as cell-free tumor DNA, ctDNA is genetic material that’s freely floating in the bloodstream of cancer patients. The source of ctDNA is the tumor, where dead tumor cells break open and release the tumor DNA into the patient’s blood.

Image credit: pixabay.com

Led by Charles Swanton from the Francis Crick Institute, researchers analyzed blood samples from 100 patients with non-small cell lung cancer, the most common type of lung cancer. These patients also provided tumor samples, from which the researcher used to build a cancer genetic profile unique to each patient. Then, they hunted for these genetic mutations in the patient’s blood biopsies.

“First, we’re looking at blood samples taken before the patients had surgery to remove their tumours,” explained Christopher Abbosh, the study’s lead author. “We want to see what features of the tumour are associated with the release of ctDNA into the circulation. Next, we want to see which parts of the tumor’s genetic make-up, or ‘evolutionary tree’, can be detected in the blood. Finally, we want to find out what this DNA could tell us after the patients have had surgery.”

This in-depth analysis dramatically increased the sensitivity of detecting ctDNA and capturing the very early stages of lung cancer relapsing. Almost all of the patients with squamous cell type lung cancer had tumor DNA in their blood.

“Many studies have suggested that tumour DNA might be released when cancer cells are breaking down and becoming necrotic,” said Abbosh. “Squamous cell tumours are known to be a necrotic type of non-small cell lung cancer, so this might explain why we could detect tumour DNA earlier in these patients.

The biggest advantage of this new technique is early detection. The researchers report that the blood test catches these tumors when they’re still tiny, occupying just 0.3 cubic millimeters. Just as it’s easier to contain small fires than big ones, treating cancer when it’s small and nearly invisible is likely to yield better outcomes. "We hope that by treating the disease when there are very few cells in the body that we'll be able to increase the chance of curing a patient,” said Swanton.

"We can identify patients to treat even if they have no clinical signs of disease, and also monitor how well therapies are working,” said Abbosh. "This represents new hope for combating lung cancer relapse following surgery, which occurs in up to half of all patients.”

But some big questions are still unanswered. "We can now set up clinical trials to ask the fundamental question - if you treat people's disease when there's no evidence of cancer on a CT scan or a chest X-ray can we increase the cure rate?” said Swanton.

Additional sources: BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 23, 2019
Cancer
NOV 23, 2019
Anal cancer rates increase twofold
Anal cancer has been on the rise in the United States, and while it may not garner as much attention as other cancers, mortality rates for anal cancer have...
NOV 25, 2019
Cancer
NOV 25, 2019
Using AI to determine which patients are best suited for immunotherapy
A new study published in the journal Cancer Immunology Research suggests that we can use artificial intelligence to help determine which people with lung c...
DEC 14, 2019
Cancer
DEC 14, 2019
Common antibiotic could improve radiation therapy
Have you ever taken the antibiotic vancomycin? As a commonly prescribed antibiotic for colitis and infections caused by Clostridium difficile, vancomycin i...
DEC 18, 2019
Drug Discovery & Development
DEC 18, 2019
A tool that simplifies the hunt for cancer drugs
Cells have long been the internal hubs for proteins that hold a wide variety of unique functions. Disorders on how a cell synthesizes a protein can affect ...
JAN 02, 2020
Drug Discovery & Development
JAN 02, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
Loading Comments...